DMK Pharmaceuticals Corp
OTC:DMKPQ
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
DMK Pharmaceuticals Corp
OTC:DMKPQ
|
10 USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
990.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
298.8B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
157.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
DMK Pharmaceuticals Corp
Glance View
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for DMK Pharmaceuticals Corp is -614.2%, which is below its 3-year median of -534.2%.
Over the last 3 years, DMK Pharmaceuticals Corp’s Net Margin has decreased from -463.6% to -614.2%. During this period, it reached a low of -6 231.3% on Jun 30, 2022 and a high of 11 738.8% on Mar 31, 2021.
